Stocks Health care EMMA
OTC · Health careEmmaus Life Sciences, Inc. (EMMA)
Emmaus Life Sciences, Inc. brought in $15.5M of revenue over the twelve months to June 30, 2026, up 11.0% from a year earlier. It posted a net loss of $6M. In fiscal 2025 capital spending exceeded operating cash flow by $12K. At June 30, 2026 it held $2.8M in cash against $25M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Watch EMMA in 60 secondsWhat Emmaus Life Sciences, Inc. does
Emmaus Life Sciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker EMMA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $12.5M | -$7.5M | -$0.12 | -$12K |
| 2024 | $16.7M | -$6.5M | -$0.10 | -$2.3M |
| 2023 | $29.6M | -$3.7M | -$0.07 | -$1.5M |
| 2022 | $18.4M | -$10.6M | -$0.21 | -$5.1M |
| 2021 | $20.6M | -$15.9M | -$0.32 | -$1.3M |
| 2020 | $23.2M | $1.4M | $0.03 | -$2.5M |
Full financial statements: income, balance sheet and cash flow
Where EMMA ranks in Health care
Latest SEC filings
What Emmaus Life Sciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 14, 2026
- August 14, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 124% to $6.3M versus the same quarter last year; diluted EPS $0.02 versus -$0.02.
- May 15, 2026
- May 15, 2026Quarterly report 10-Q · period to March 31, 2026Revenue fell 18% to $2M versus the same quarter last year; diluted EPS -$0.05 versus -$0.04.
- April 17, 2026
- April 14, 2026
- March 31, 2026
- March 31, 2026Annual report 10-K · period to December 31, 2025Revenue fell 25% to $12.5M versus the prior year; diluted EPS -$0.12 versus -$0.10.
- March 4, 2026
- December 31, 2025
Insider trades
What the people running Emmaus Life Sciences, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $15K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 31, 2026 | Lee Willis CCEO, Director | Boughtindirect | 100,000 | $5K |
| August 28, 2026 | Lee Willis CCEO, Director | Boughtindirect | 94,767 | $5.7K |
| August 27, 2026 | Lee Willis CCEO, Director | Boughtindirect | 50,000 | $2.5K |
| August 25, 2026 | Lee Willis CCEO, Director | Boughtindirect | 46,000 | $1.8K |
Who owns EMMA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
Largest institutional holders
Insiders
1 insiders reported holding 690,167 shares in total, about $46.8K at the last price.
| Holder | Shares |
|---|---|
| Lee Willis CCEO, Director | 690,167690,167 held indirectly |
Questions about EMMA
What does Emmaus Life Sciences, Inc. do?
Emmaus Life Sciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker EMMA.
Is Emmaus Life Sciences, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $6M on revenue of $15.5M.
How much revenue does Emmaus Life Sciences, Inc. make?
Over the twelve months to June 30, 2026 Emmaus Life Sciences, Inc. reported revenue of $15.5M. That is 11.0% more than a year earlier.
When did Emmaus Life Sciences, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 2, 2026.
Similar companies
Compare EMMA with
Follow EMMA
Get an email when Emmaus Life Sciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow EMMA: get an email when it filesWhere the numbers come from
Financial figures are the values Emmaus Life Sciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.